Kyriakopoulos CE et al., 2018-04-10: The long-term CHAARTED analysis reports a 16.8-month median survival gain in high-volume disease (51.2 vs 34.4 months; HR 0.63) and no confirmed benefit in low-volume disease (63.5 months vs not reached; HR 1.04; P=.86), with significant interaction by volume (P=.033).
in the low-volume subgroup, with a median follow-up of 53.8 months, a survival benefit from docetaxel was not confirmed (median OS, 63.5 months for the chemohormonal arm v not reached for the ADT alone arm; HR for death in the combination arm, 1.04; 95% CI, 0.70 to 1.55; P = .86)
Results (PMC HTML, unpaginated)
Kyriakopoulos CE et al., 2018-04-10: The long-term CHAARTED analysis reports a 16.8-month median survival gain in high-volume disease (51.2 vs 34.4 months; HR 0.63) and no confirmed benefit in low-volume disease (63.5 months vs not reached; HR 1.04; P=.86), with significant interaction by volume (P=.033). Funder: NCI/ECOG-ACRIN per the 2015 NEJM report (same trial); Sanofi supplied docetaxel. Conflicts: the JCO disclosure appendix is not rendered in the PMC text – verifier should check the JCO PDF for individual disclosures (several authors report Sanofi advisory roles in this period). Maker: Sanofi. Comparator: ADT alone. Correction: the low-volume HR of 1.04 is a null, not a proven harm, result. Study type: randomized trial.
